Effectiveness of Swasakudori Mathirai for childhood bronchial asthma

An open non randomized single arm single centric clinical trial to determine the effectiveness of Swasakudori Mathirai in the management of Sooli Kanam(childhood asthma) in children. - ESMCHI

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/06/043567

Enrollment

Registered

2022-06-29

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: Swasakudori mathirai: Swasakudori mathirai dosage- 6-7years-90mg tablet,8-12years -130mg tablet with Thalisapathiri kudineer 6-7years-20ml,8-12years-30ml twice a day for 48 days Control

Eligibility

Inclusion criteria

Inclusion criteria: children with minimum 3-4 clinical symptoms of bronchial asthma may be included, 1.Cough 2.Wheezing 3.Tightness of chest 4.Abdominal bloating, shortness of breath. 5.Peak expiratory flow rate more than 50%(mild, moderate exacerbation)

Exclusion criteria

Exclusion criteria: 1.Peak expiratory flow rate less than 50%(severe exacerbation) 2.Congenital heart diseases 3.Pneumonia 4.H/o pulmonary tuberculosis 5.Any other serious illness

Design outcomes

Primary

Measure	Time frame
PRIMARY OUTCOME: Effectiveness of the trial drug is measured by peak expiratory flow meter.Timepoint: Screening - 3 months Patient Enrolment - 3 months Trial Drug - 4 months Data Analysis - 1 month Follow up - 1 month	—

Secondary

Measure	Time frame
Reduction of clinical symptoms by using PASS SCORE. Timepoint: fourty ninth day.	—

Countries

India

Contacts

Public ContactDr M Meenakshi Sundaram MDS PhD

National Institute of Siddha

mmssiddha@gmail.com9444214582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026